LOS ALTOS, Aug. 14, 2024. RenovoRx (Nasdaq: RNXT), a clinical-stage biopharmaceutical company
developing novel precision oncology therapies based on a local drug-delivery platform,
announced today that the first patient has been enrolled at the University of Nebraska
Medical Center (“UNMC”) in RenovoRx’s ongoing pivotal Phase III TIGeR-PaC clinical trial
for Locally Advanced Pancreatic Cancer (LAPC).
Ends
Imugene in collaboration with Renovo will be using the Tamp delivery system in future trials.
The market is unmoved so far but I'm loving it, bring it on!
Media Thread, page-15086
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.1¢ | 4.8¢ | $1.062M | 21.65M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 5138497 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 6291273 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |